home / stock / hrtx / hrtx news

HRTX News and Press, Heron Therapeutics Inc. From 05/29/19

Stock Information
Company Name: Heron Therapeutics Inc.
Stock Symbol: HRTX
Market: NASDAQ
Website: herontx.com
Menu
HRTX HRTX Quote HRTX Short HRTX News HRTX Articles HRTX Message Board
Get HRTX Alerts

News, Short Squeeze, Breakout and More Instantly...
HRTX - Heron Therapeutics to Present at Jefferies 2019 Healthcare Conference

SAN DIEGO , May 29, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that...
HRTX - Heron Therapeutics Announces Publication of Results from Phase 3 EPOCH 1 Study of HTX-011 in Patients Undergoing Bunionectomy

SAN DIEGO , May 21, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that...

HRTX - Heron Therapeutics Presents New Results from Real-world Study Showing 95% of Postoperative Patients Remain Opioid-Free when HTX-011 Is Given with an Over-the-Counter Analgesic Regimen

SAN DIEGO , May 14, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced resu...

HRTX - Heron Therapeutics misses by $0.31, beats on revenue

Heron Therapeutics (NASDAQ: HRTX ): Q1 GAAP EPS of -$0.80 misses by $0.31 . More news on: Heron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

HRTX - Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress

SAN DIEGO , May 9, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced finan...

HRTX - Heron Therapeutics to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference

SAN DIEGO , May 8, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that ...

HRTX - Heron's CRL Is Just A Minor Bump And Resubmission For Approval Will Come Quickly

Heron Therapeutics ( HRTX ) announced that the FDA had given a complete response letter ((CRL)) for HTX-011 for the treatment of patients with postoperative pain. I believe that this is a temporary delay for approval, because the issue noted in the CRL is an easy matter to resolve. The b...
HRTX - Heron Therapeutics Partners with the National Academy of Medicine to Counter the Opioid Epidemic in the United States

SAN DIEGO , May 7, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced they ...

HRTX - Biotech News Recap: Biogen Reports Promising Data In ALS, Still Facing Several Challenges

Biogen ( BIIB ) - The company announced interim results from a phase 1/2 study of tofersen (antisense oligonucleotide) being studied for the treatment of amyotrophic lateral sclerosis ((ALS)). Data was sufficiently encouraging to support initiation of phase 3 study in SOD1-ALS patients and ...

HRTX - Heron: In The Middle Of Every Difficulty Lies Opportunity

You don't make money when you buy stocks. And you don't make money when you sell stocks. You make money by waiting - The Dhando Investor (Mohnish Pabrai) According to Integrated BioSci Investing, being "opportunistic" is one of the requisites to successful capital allocation. Stellar inves...
Previous 10 Next 10